Control and prevention of cystitis
What is Utipro® Plus AF
Utipro® Plus AF is a medical device based on xyloglucan and gelose.
It acts mechanically in the intestinal lumen, impairing the contact of the pathogens with the intestinal mucosa, which is the first step for bacterial proliferation and their subsequent passage to the urinary tract.
Intended use
Utipro® Plus AF is intended for the control of symptoms of cystitis as well as for the prevention of new episodes.
How it works
Utipro® Plus AF creates a protective barrier on the intestinal mucosa, helping to:
- Avoid adhesion of uropathogenic bacteria
- Reduce bacterial proliferation
- Limit bacteria migration to the urinary tract
- Avoid installation of intestinal bacterial reservoir
Who is Utipro® Plus AF for and how to use it
It is intended for use in adolescents aged 14 years and older and in adults.
Utipro® Plus AF is to be taken orally from the appearance of the first symptoms of urinary tract disorders, one capsule every 12 hours for five days, to reduce the proliferation of pathogens that may degenerate into infections.
In case of recurrent cystitis, take one capsule of Utipro® Plus AF per day for 15 consecutive days per month, to prevent new episodes generally caused by the intestinal bacterial reservoir. If required, the treatment can be maintained for 6 months.
Additional information
Utipro® Plus AF is a substance-based medical device that holds MDR certification, Class III, issued by the NB CE 0476
No relevant side effects related to the use of Utipro® Plus AF have been reported in clinical studies.
Utipro® Plus AF is mentioned in the guidelines of the European Association of Urologists (EAU) as the non-antibiotic approach to cystitis with the highest level of scientific evidence.
Utipro® Plus AF does not have bactericidal or bacteriostatic properties therefore cannot substitute antibiotic treatment when needed but it can, however, be administered concomitantly.
Utipro® Plus AF is:
- Capsules: 15s / 30s
Clinical studies and publications, as well as the Product Information leaflet (PIL), and the Summary on Safety and Clinical Perfromance (SSCP), are available upon request.
For more information, including clinical trial data and dossier details, please contact us.
CE mark + MDR Class III note
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.